Chromatine/Épigénétique
Les inhibiteurs de la chromatine/épigénétique sont des composés qui modulent la structure et la fonction de la chromatine ou interfèrent avec les modifications épigénétiques, telles que la méthylation de l'ADN et la modification des histones. Ces inhibiteurs sont des outils essentiels pour étudier la régulation de l'expression génique et le rôle de l'épigénétique dans des maladies telles que le cancer, les troubles neurologiques et les anomalies du développement. En ciblant les processus épigénétiques, ces inhibiteurs peuvent modifier les schémas d'expression génique et offrir de nouvelles perspectives thérapeutiques. Chez CymitQuimica, nous offrons une large sélection d'inhibiteurs de la chromatine/épigénétique de haute qualité pour soutenir vos recherches en biologie moléculaire, génétique et épigénétique.
Sous-catégories appartenant à la catégorie "Chromatine/Épigénétique"
2553 produits trouvés pour "Chromatine/Épigénétique"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
PROTAC BRD4 Degrader-25
CAS :PROTAC BRD4 Degrader-25 (Compound 1-f), a targeted BRD4 degrader, is utilized in the study of cancer and additional diseases related to bromodomains [1].Formule :C34H30FN9O2SCouleur et forme :SolidMasse moléculaire :647.72PARP10/15-IN-1
PARP10/15-IN-1 (compound 8l) is a dual PARP10 and PARP15 inhibitor with IC50s of 160 nM and 370 nM, respectively. It can be used in cancer research[1].Formule :C13H10N2O3SCouleur et forme :SolidMasse moléculaire :274.3Pim-1 kinase inhibitor 3
CAS :Pim-1 kinase inhibitor 3 (Compound H5) is a potent inhibitor of Pim-1 kinase, demonstrating an inhibitory concentration (IC50) of 35.13 nM [1].Formule :C20H25N3O2Couleur et forme :SolidMasse moléculaire :339.43BRD4-IN-9
CAS :BRD4-IN-9, an orally active BRD4 inhibitor, demonstrates a potent IC50 of 9.4 nM. In a murine melanoma xenograft model, it effectively inhibits tumor growth.Formule :C24H23N3O3Couleur et forme :SolidMasse moléculaire :401.46STR-V-53
CAS :STR-V-53, an HDAC inhibitor (IC50 in nM), increases histone acetylation in tumor cells by inhibiting these enzymes, thereby regulating gene expression. STR-V-53 inhibits tumor growth and induces apoptosis [1].Formule :C21H30N4O8Couleur et forme :SolidMasse moléculaire :466.48Sirtuin-IN-2
Sirtuin-IN-2 (compound 20) is an inhibitor of Sirtuin5, a key target in leukemia and breast cancer.Formule :C28H46N8O6SCouleur et forme :SolidMasse moléculaire :622.78MC3138
CAS :MC3138 is a selective SIRT5 activator showing anti-tumor effects in PDAC cells.Formule :C25H25NO6Degré de pureté :99.57%Couleur et forme :SolidMasse moléculaire :435.47(2S,3R)-LP99
CAS :(2S,3R)-LP99 is a less active enantiomer of LP99.Formule :C26H30ClN3O4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :516.05PARP1-IN-5
PARP1-IN-5 is a potent, selective, orally active, low-toxicity PARP-1 inhibitor with an IC50 value of 14.7 nM. PARP1-IN-5 can be used in cancer research.Formule :C25H24N2O5SCouleur et forme :SolidMasse moléculaire :464.53SE-7552
CAS :SE-7552, a derivative of 2-(difluoromethyl)-1,3,4-oxadiazole (DFMO), serves as an orally active, highly selective non-hydroxamate HDAC6 inhibitor, boasting an IC50 of 33 nM. It exhibits over 850-fold selectivity against all other known HDAC isozymes. Demonstrating efficacy in vivo, SE-7552 effectively inhibits the growth of multiple myeloma. Additionally, it functions as an anti-obesity agent in diet-induced obese mice [1] [2].
Formule :C15H12F3N5OCouleur et forme :SolidMasse moléculaire :335.28JAK3-IN-7
CAS :JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction afterFormule :C17H20N6ODegré de pureté :98.81%Couleur et forme :SolidMasse moléculaire :324.38AFM-30a hydrochloride
AFM-30a hydrochloride: selective PAD2 inhibitor, EC50 9.5 μM; blocks H3 guanylation, EC50 0.4 μM; used for cancer and autoimmune research.Formule :C24H28ClFN6O3Couleur et forme :SolidMasse moléculaire :502.97IBL-302
CAS :IBL-302 (AMU302), an orally available dual-signaling inhibitor targeting PIM and PI3K/AKT/mTOR, is effective against breast cancer and neuroblastoma. It has shown in vivo efficacy in a nude mouse xenograft model by combating trastuzumab resistance. Additionally, IBL-302 augments the effectiveness of widely used cytotoxic chemotherapy drugs such as cisplatin, doxorubicin, and etoposide [1] [2] [3].Formule :C25H18FN5O4S3Couleur et forme :SolidMasse moléculaire :567.64PAD4-IN-5
CAS :PAD4-IN-5 (Example 18) is a PAD4 inhibitor with an IC50 of ≤10 nM at 50 µM Ca2+ and 101-500 nM at 1 mM Ca2+ against human PAD4 (hPAD4). This compound is applicable in the study of autoimmune diseases such as rheumatoid arthritis (RA).Formule :C34H41N7O3Couleur et forme :SolidMasse moléculaire :595.734PARP14 inhibitor 2
CAS :PARP14 inhibitor2 (Compound 3) is an orally active and highly selective PARP14 inhibitor with an IC50 value of less than 30 nM. It effectively inhibits the mono ADP-ribosyltransferase activity of PARP14 and modulates IFN-γ and IL-4 signaling, thereby reversing pro-tumor macrophage polarization and suppressing anti-tumor inflammatory responses. PARP14 inhibitor2 holds potential for research in PARP14-related conditions such as tumors, atopic dermatitis, and autoimmune diseases.Formule :C25H32FN3O4SCouleur et forme :SolidMasse moléculaire :489.606K465
CAS :6K465 is a potent Aurora A kinase inhibitor that reduces c-MYC and N-MYC oncoproteins, showing antiproliferative effects in SCLC and breast cancer cell lines.Formule :C26H33ClFN9ODegré de pureté :99.78%Couleur et forme :SolidMasse moléculaire :542.05SARS-CoV-2 nsp14-IN-1
SARS-CoV-2 nsp14-IN-1 inhibits Nsp14 Mtase with an IC50 of 0.061 μM, affecting multiple substrates.Formule :C20H20N6O5SCouleur et forme :SolidMasse moléculaire :456.48BRD4 D1-IN-2
BRD4 D1-IN-2 (compound 26), a BRD4 D1 inhibitor, IC50 <0.092 μM, 15 nM affinity, >500x selectivity over BRD2 D1/BRD4 D2.Formule :C33H39F3N6OCouleur et forme :SolidMasse moléculaire :592.7BRD4 D1-IN-1
BRD4 D1-IN-1 selectively inhibits BRD4 D1 (IC50 <0.092 μM, Kd 18 nM) with >500-fold specificity versus D2.Formule :C32H37F3N6OCouleur et forme :SolidMasse moléculaire :578.67SCR-7952
CAS :SCR-7952, a MAT2A inhibitor, is utilized in cancer research.Formule :C19H15ClN4OCouleur et forme :SolidMasse moléculaire :350.80NI-Pano
NI-Pano (CH-03) is a novel hypoxia-activated KDAC inhibitor capable of O2-dependent release of the compound panobinostat.Formule :C26H28N6O4Couleur et forme :SolidMasse moléculaire :488.54KCL-440
CAS :RS 57639 is a bioactive chemical.Formule :C18H18N2O2Couleur et forme :SolidMasse moléculaire :294.35Balomenib
CAS :Balomenib is an inhibitor of the menin-MLL interaction, effectively blocking the men1-MLL4-43 interaction with an IC50 of less than 0.075 μM. It inhibits cell growth in MV4-11 (CC50 < 0.1 μM), MOLM-13 (CC50 0.1~0.5 μM), and HEK293 (CC50 < 2 μM) cells. Balomenib also exhibits antitumor activity.Formule :C33H34F3N7O2Couleur et forme :SolidMasse moléculaire :617.664iBRD4-BD1 diTFA
CAS :iBRD4-BD1 diTFA is a selective BRD4 bromodomain inhibitor with an IC50 value of 12 nM. It can be used for research in inflammation and oncology [1].Formule :C33H32F9N5O5Couleur et forme :SolidMasse moléculaire :749.62GSK3368715 3HCl
CAS :GSK3368715, a potent inhibitor of type I protein arginine methyltransferases (PRMT), could inhibit PRMT1, 3, 4, 6 and 8 with Kiapp vaules ranging from 1.5 to 81Formule :C20H41Cl3N4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :475.92BRD9 Degrader-2
CAS :BRD9 Degrader-2 (Compound B11), a potent BRD9 degrader (DC50≤1.25nM; Dmax≥75%), is applicable in cancer research.Formule :C40H43F3N6O4SCouleur et forme :SolidMasse moléculaire :760.87RK-582
CAS :RK-582: oral spiroindolinone tankyrase inhibitor, halts colon cancer growth in COLO-320DM mouse model.Formule :C27H35FN6O3Couleur et forme :SolidMasse moléculaire :510.6Streptonigrin (racemate)
CAS :Streptonigrin: aminoquinone antibiotic; antitumor, antibacterial; blocks β-Catenin/Tcf, cytotoxic; alters hamster chromosomes; (-)-isomer, CAS#3930-19-6.Formule :C25H22N4O8Couleur et forme :SolidMasse moléculaire :506.46XP-524
CAS :XP-524: BET & EP300 inhibitor, suppresses KRAS tumors in vivo, targets PDAC, boosts immune response.Formule :C30H28N6O3SCouleur et forme :SolidMasse moléculaire :552.65EN884
CAS :EN884 is a BRD4 degrader that functions through an SKP1 and proteasome-dependent degradation pathway. It is utilized in the synthesis of proteolysis-targeting chimeras (PROTAC).Formule :C14H18N2OMasse moléculaire :230.31HDAC6-IN-51
CAS :HDAC6-IN-51 (Compound 7e) is a selective inhibitor of HDAC6, exhibiting an IC50 value of 42.9 nM. This compound demonstrates effective anti-pulmonary fibrosis activity.Formule :C24H24ClN5O3Couleur et forme :SolidMasse moléculaire :465.93DS44470011
CAS :DS44470011 is an inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) with oral bioavailability. It enhances the release of erythropoietin (EPO) from cells and is utilized in research related to renal anemia.Formule :C21H19N3O4Couleur et forme :SolidMasse moléculaire :377.39W4275
CAS :W4275 (Compound 42) is a selective NSD2 inhibitor with oral activity and an IC50 of 17 nM. It exhibits antiproliferative activity, with an IC50 of 230 nM against RS411 cells, and significantly inhibits tumor growth in an RS411 tumor xenograft model. Pharmacokinetic analysis in mice shows that W4275 has a favorable oral bioavailability (F is 27.34%). W4275 holds potential for use in cancer research.Formule :C25H36N6O3Couleur et forme :SolidMasse moléculaire :468.59PRMT5-IN-1 hydrochloride
PRMT5 IN-1 hydrochloride is a potent PRMT5 inhibitor (IC50: 11 nM), forms covalent adduct with C449, and converts to an aldehyde in vivo.Formule :C19H20Cl2N4O5Couleur et forme :SolidMasse moléculaire :455.29Pim-1 kinase inhibitor 6
CAS :Pim-1 kinase inhibitor 6 (Compound 4d) is a robust inhibitor of Pim-1 kinase, demonstrating an IC 50 of 0.46 μM. It significantly exhibits cytotoxic effects on cancer cells [1].Formule :C21H10BrCl2N3Couleur et forme :SolidMasse moléculaire :455.13BET-IN-1
BET-IN-1 is a potent inhibitor of BET, exhibiting good brain permeability and a reasonable metabolic stability.Formule :C23H24ClFN4O3SCouleur et forme :SolidMasse moléculaire :490.98PRMT5-IN-1
CAS :PRMT5-IN-1 is a covalent inhibitor of protein arginine methyltransferase 5 (PRMT5)(IC50 of 11 nM for PRMT5/MEP50).Formule :C19H19ClN4O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :418.83NSD2-PWWP1-IN-2
CAS :NSD2-PWWP1-IN-2 (compound 33) is a potent NSD2-PWWP1 inhibitor, exhibiting an IC50 value of 1.49 µM, indicating its potential utility in cancer research.Formule :C29H30N4Couleur et forme :SolidMasse moléculaire :434.575P300-IN-4
P300-IN-4 (compound 6) is a histone acetyltransferase p300 inhibitor with an IC50 value of 12.2 μM.Formule :C29H28ClIN4O5Couleur et forme :SolidMasse moléculaire :674.91Bromodomain inhibitor-13
CAS :Bromodomain Inhibitor-13 (Compound 1), an analog of PFI-3, is a bromodomain-containing protein (BCP) inhibitor. It specifically targets the bromodomains of SMARCA2, SMARCA4, and the first and second bromodomains of PB1 [PB1(5) and PB1(2)], with dissociation constants (KD) of 37, 53, 30, and 190 nM, respectively.Formule :C21H22N4O2Couleur et forme :SolidMasse moléculaire :362.43KH-259
KH-259: potent, selective CNS-penetrant HDAC6 inhibitor with 0.26 μM IC50; shows antidepressant effects in mice.Formule :C20H25N3O2Couleur et forme :SolidMasse moléculaire :339.43HDAC1-IN-3
HDAC1-IN-3 is a potent inhibitor of Pf HDAC1.Formule :C22H24ClN7O2Couleur et forme :SolidMasse moléculaire :453.92SMARCA2-IN-6
CAS :SMARCA2-IN-6 is a potent inhibitor of SMARCA2 (also known as BRM), exhibiting an IC50 of less than 5 nM against both SMARCA2 and SMARCA4. Additionally, this compound suppresses the expression of the KRT80 gene in H1299 cells with an IC50 of 26 nM and inhibits the proliferation of SKMEL5 cells carrying a BRG1 mutation with an IC50 value of 13 nM.Formule :C10H8ClF2N5OSCouleur et forme :SolidMasse moléculaire :319.72DS79932728
CAS :DS79932728 is an orally active inhibitor of G9a and GLP, with IC50 values of 12.6 nM and 75.7 nM, respectively. It induces the production of γ-globin, thereby increasing fetal hemoglobin (HbF) levels. In cynomolgus monkey models, DS79932728 enhances the proportion of F-reticulocytes (F-rets) and shows good oral absorption characteristics.Formule :C19H25N3OCouleur et forme :SolidMasse moléculaire :311.421CBP/p300-IN-18
CBP/p300-IN-18 (compound 8) is a potent inhibitor of EP300/CBP HAT, acting on HAT EP300 (IC50: 0.056 μM) and LK2 H3K27 (IC50: 0.46 μM).Formule :C25H27FN4O3Couleur et forme :SolidMasse moléculaire :450.51SIRT6 activator 2
CAS :SIRT6 activator2 (compound 31) is a sirtuin6 activator known for its anti-lipid accumulation properties. It significantly downregulates LXR, SREBP-1c, and their target genes, making it valuable for research into lipid metabolism-related diseases.Formule :C23H23N3O6Couleur et forme :SolidMasse moléculaire :437.45BSI-401
CAS :BSI-401 is an oral inhibitor of PARP-1. It can inhibit pancreatic cancer either when used alone or in synergy with Oxaliplatin.Formule :C9H4INO4Couleur et forme :SolidMasse moléculaire :317.037KDOAM-25 trihydrochloride
KDOAM-25 trihydrochloride selectively inhibits KDM5 enzymes, boosts H3K4 methylation, and suppresses MM1S cell growth.Formule :C15H28Cl3N5O2Couleur et forme :SolidMasse moléculaire :416.77LSD1-IN-19
LSD1-IN-19 is a potent, selective LSD1 inhibitor with Ki of 0.108 μM and 72h IC50 values of 0.17-0.40 μM.Formule :C33H42N6O2Couleur et forme :SolidMasse moléculaire :554.73PKCiota-IN-1
CAS :PKCiota-IN-1: Strong PKC-ι inhibitor (IC50=2.7 nM); also blocks PKC-α/ε (IC50s=45/450 nM).Formule :C25H22FN5OCouleur et forme :SolidMasse moléculaire :427.47LSD1-IN-16
LSD1-IN-16 (4b) inhibits LSD1, MAO-A/B; IC50: 0.015-0.366 μM. Halts prostate cancer cell growth; IC50: 15.2 μM.Formule :C20H18N2OSCouleur et forme :SolidMasse moléculaire :334.43PRMT5-IN-37
CAS :PRMT5-IN-37 (compound 29), an orally active inhibitor of PRMT5, is utilized for cancer research.Formule :C21H15F4N5O2Couleur et forme :SolidMasse moléculaire :445.37MS117
MS117 is a first-in-class and cell-active irreversible covalent inhibitor of protein arginine methyltransferase 6 (PRMT6) (IC50 = 18 nM) [1].Formule :C17H22N4OCouleur et forme :SolidMasse moléculaire :298.38Aurora/LIM kinase-IN-1
Aurora/LIM kinase-IN-1 (Compound F114) is a dual inhibitor targeting aurora and lim kinases, potentially useful in GBM cancer treatment efforts.Formule :C16H20N6OCouleur et forme :SolidMasse moléculaire :312.37PARP1-IN-30
CAS :PARP1-IN-30 is a specific and effective PARP1 inhibitor with cytotoxic properties. It precisely inhibits PARP1 in tumor cells lacking breast cancer 1 protein (BRCA1) or BRCA2. PARP1-IN-30 holds potential for use in cancer research.Formule :C14H12ClNO4SCouleur et forme :SolidMasse moléculaire :325.77O6BTG-C8-αGlu
CAS :O6BTG-C8-αGlu is an O6-methylguanine-DNA methyltransferase (MGMT) inhibitor with an IC50 of 0.45 μM. At a concentration of 0.1 μM, it fully inhibits MGMT in HeLaS3 cells and demonstrates no cytotoxicity even at prolonged high doses (up to 20 μM). This compound is suitable for research on MGMT-related cancers.Formule :C24H34BrN5O7SCouleur et forme :SolidMasse moléculaire :616.525WDR5-IN-5
CAS :WDR5-IN-5: Selective oral inhibitor for WDR5's WIN site with high affinity (Ki<0.02 nM) and anti-cancer properties. Good pharmacokinetics.Formule :C29H29F3N6OCouleur et forme :SolidMasse moléculaire :534.58PARP-1-IN-1
PARP-1-IN-1: Selective, oral PARP-1 inhibitor with 0.96 nM IC50; well-tolerated and effective in single-dose MDA-MB-436 model.Formule :C23H25FN4OCouleur et forme :SolidMasse moléculaire :392.47MAO A/HDAC-IN-1
MAO A/HDAC-IN-1 is an effective monoamine oxidase A (MAO A) and HDAC dual inhibitor, which can be used for glioma research.Formule :C21H24ClN3O3Couleur et forme :SolidMasse moléculaire :401.89JPHM-2-167
CAS :PHM-2-167 (Compound 11) is a selective inhibitor of the prolyl hydroxylase domain enzyme (PHD). It inhibits PHD2 and PHD3 with IC50 values of 0.253 μM and 3.95 μM, respectively. PHM-2-167 is applicable for research in chronic kidney disease.Formule :C30H28N6O2Couleur et forme :SolidMasse moléculaire :504.582Trichostatin A S-isomer
CAS :Trichostatin A S-isomer, a HDAC 1, 3, 4, 6, 10 inhibitor with IC50 ~20 nM, has wide-ranging epigenetic effects.Formule :C17H22N2O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :302.37Menin-MLL inhibitor 26
CAS :Menin-MLL inhibitor 26: Active reference, inhibits cell growth, used in leukemia research.Formule :C27H29F3N6O3SCouleur et forme :SolidMasse moléculaire :574.62HDAC/HSP90-IN-4
HDAC/HSP90-IN-4 inhibits HDAC (20 IC50=194nM, 26 IC50=360nM) & HSP90α (20 IC50=153nM, 26 IC50=77nM), affects cancer cell survival and invasion.Formule :C20H23N3O6Couleur et forme :SolidMasse moléculaire :401.15869HYDAMTIQ
CAS :HYDAMTIQ, a PARP-1/2 inhibitor (IC 50 : 29-38 nM), exhibits a range of pharmacological effects including anticancer, anti-inflammatory, and ischemic protective properties. It effectively reduces pulmonary PARP activity and alleviates symptoms such as allergen-induced cough and dyspnea while also diminishing bronchial hyperresponsiveness to methacholine. Moreover, HYDAMTIQ shows potent tumor suppressor activity in various cancers such as ovarian, breast, prostate, pancreatic, and glioblastoma multiforme. Demonstrating in vivo efficacy, HYDAMTIQ has been tested in animal models for conditions like cerebral ischemia, asthma, and cancer [1].Formule :C14H14N2O2SCouleur et forme :SolidMasse moléculaire :274.34TAF1 ligand 1
CAS :TAF1 ligand 1 is a TAF1 ligand. It can serve as a ligand for target proteins (Ligands for Target Protein for PROTAC) in the synthesis of PROTACs targeting TAF1, such as ZS3-046.Formule :C23H23N5O3Couleur et forme :SolidMasse moléculaire :417.46GSK852
GSK852 is a potent, second bromodomain (BD2)-selective, bromo and extra-terminal domain (BET) inhibitor with pIC50 of 7.9.Formule :C24H26N2O4Couleur et forme :SolidMasse moléculaire :406.47SRI-43265
CAS :SRI-43265 (compound 40) inhibits the dimerization of human antigen R protein (HuR), which is involved in cancer and inflammation pathogenesis [1].Formule :C19H20N6OCouleur et forme :SolidMasse moléculaire :348.4DS-9300
CAS :DS-9300, an orally administered potent and selective inhibitor of EP300/CBP HAT, exhibits a significant inhibitory activity with an IC50 value of 28 nM.Formule :C25H26F3N5O3Couleur et forme :SolidMasse moléculaire :501.50Sapintoxin D
CAS :Sapintoxin D is a fluorescent phorbol ester and selective activator of protein kinase C.Formule :C30H37NO8Couleur et forme :SolidMasse moléculaire :539.62GSK8814
CAS :GSK8814 is a selective and ATAD2/2B bromodomain chemical probe and inhibitor (binding constant pKd=8.1 and a pKi=8.9 in BROMOscan).Formule :C28H35F2N5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :527.61Tyk2-IN-15
CAS :Tyk2-IN-15 (Compound 97) is a selective inhibitor of tyrosine kinase 2 (Tyk2) with an IC50 value ≤ 10 nM for Tyk2-JH2. It is utilized in the research of inflammatory and autoimmune diseases [1].
Formule :C21H25F2N7OCouleur et forme :SolidMasse moléculaire :429.47Menin-MLL inhibitor 4
CAS :Menin-MLL inhibitor 4 has antitumor activity.Menin-MLL inhibitor 4 is an inhibitor of Menin- MLL (mixed-lineage leukemia protein) interaction .Formule :C32H38FN7O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :587.69PARP1-IN-29
CAS :PARP1-IN-29 is an orally active PARP-1 inhibitor with an IC50 of 6.3 nM. When labeled with [18F], PARP1-IN-29 can be utilized for positron emission tomography (PET) imaging, specifically targeting PARP-1 in tumors. This compound is useful in oncology and imaging studies, particularly for detecting PARP-1 activity in cancer.Formule :C18H16FN3O2Couleur et forme :SolidMasse moléculaire :325.34JAK1/TYK2-IN-3
JAK1/TYK2-IN-3, orally active, selectively inhibits TYK2 (IC50: 6 nM), JAK1 (37 nM), JAK2 (140 nM), JAK3 (362 nM), and has anti-inflammatory effects.Couleur et forme :SolidSIRT1-IN-5
CAS :SIRT1-IN-5 (215) is a modulator of NAD-dependent deacetylase SIRT1 with potential applications in cancer and cellular signaling research.Formule :C21H17N3O3SDegré de pureté :99.97%Couleur et forme :SolidMasse moléculaire :391.44LSD1-IN-18
LSD1-IN-18 inhibits LSD1 (Ki: 0.156 μM, KD: 0.075 μM), blocking THP-1 and MDA-MB-231 cell growth (IC50: 0.16, 0.21 μM).Formule :C31H40N6O2Couleur et forme :SolidMasse moléculaire :528.69CP-352664
CAS :CP-352664 is a JAK inhibitor with potency against JAK3, exhibiting an EC50 value of 210 nM. It holds potential for use in research related to organ transplant rejection and autoimmune diseases, such as rheumatoid arthritis.Formule :C18H18N4Couleur et forme :SolidMasse moléculaire :290.36JAK-IN-23
"JAK-IN-23: oral dual JAK/STAT & NF-κB inhibitor; JAK1 (IC50: 8.9 nM), JAK2 (15 nM), JAK3 (46.2 nM); for IBD research."Formule :C23H22Cl2N4OCouleur et forme :SolidMasse moléculaire :441.35TYK2 ligand 2
CAS :TYK2ligand 2 is the TYK2 ligand of PROTACTYD-68. TYD-68 is a highly potent and selective CRBN-recruiting TYK2 PROTAC degrader with a DC50 value of 0.42 nM.Formule :C24H20FN7O4Couleur et forme :SolidMasse moléculaire :489.458cis-4-Br-2,5-F2-PCPA
cis-4-Br-2,5-F2-PCPA (S1024) blocks LSD1/LSD2 (Ki: 94 nM/8.4 μM), hinders cancer stem cell growth, raises H3K4me2 in CCRF-CEM cells.Formule :C9H8BrF2NCouleur et forme :SolidMasse moléculaire :248.07HDAC-IN-47
HDAC-IN-47: Oral HDAC inhibitor (IC50: 19.75-302.73 nM for HDAC1-8), blocks G2/M, inhibits autophagy, triggers apoptosis, anti-cancer in vivo.Formule :C17H20BrN3O4Couleur et forme :SolidMasse moléculaire :410.26JAK2 JH2 binder-1
CAS :JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.Formule :C29H25N7O6SCouleur et forme :SolidMasse moléculaire :599.62LNK01004
CAS :LNK01004 is a JAK inhibitor that exhibits potent inhibitory effects on JAK1 (IC50: 10 nM), JAK2 (IC50: ＜0.51 nM), and TYK2 (IC50: 1.0 nM). It can concurrently inhibit multiple cytokine-induced p-STAT signaling pathways and is applicable for research on diseases such as atopic dermatitis.Formule :C26H31N7O2Couleur et forme :SolidMasse moléculaire :473.57Ten01
Ten01 exhibits a 5.0 nM inhibition of JAK1 kinase.Formule :C18H20F6N4OCouleur et forme :SolidMasse moléculaire :422.37Itareparib
CAS :Itareparib is a PARP inhibitor with demonstrated antitumor activity.Formule :C20H26FN3O2Couleur et forme :SolidMasse moléculaire :359.438Aurora A inhibitor 1
CAS :Aurora A inhibitor 1: potent, selective, targets cancer-linked Aurora A overexpression, potential for cancer research. (WO2021147974A1, 49)Formule :C25H28ClF2N5O2Couleur et forme :SolidMasse moléculaire :503.97HDAC6-IN-12
HDAC6-IN-12 is a potent inhibitor of HDAC6 that binds in the DNA chain, causing DNA damage and exhibiting anticancer effects that can be used in cancer researchFormule :C24H39F2N3O5Couleur et forme :SolidMasse moléculaire :487.58NSD2-PWWP1-IN-1
CAS :NSD2-PWWP1-IN-1 (compound 31) is a potent inhibitor of NSD2-PWWP1 with an IC50 value of 0.64 µM, demonstrating potential applications in cancer research.Formule :C28H30N4Couleur et forme :SolidMasse moléculaire :422.565SMARCA2/4-ligand-5
CAS :SMARCA2/4-ligand-5 is the target protein ligand of PROTAC SMARCA2/4 degrader-37 (Example 4). PROTAC SMARCA2/4 degrader-37 (Example 4) is a PROTAC degrader of SMARCA2/4, with an IC50 value of ≤0.1 μM.Formule :C20H13ClN4O3Couleur et forme :SolidMasse moléculaire :392.795AZ0108
CAS :AZ0108, an oral PARP1,2,6 inhibitor, selectively blocks centrosome clustering, is viable for in vivo studies, and doesn't inhibit PARP3/TNKS1.Formule :C24H20F4N6O2Couleur et forme :SolidMasse moléculaire :500.45GSK789
CAS :GSK789 is a selective inhibitor of the first bromodomains (BD1) of the bromo and extra terminal domain (BET) proteins.Formule :C26H33N5O3Couleur et forme :SolidMasse moléculaire :463.57Zavondemstat L-lysine
CAS :Zavondemstat (L-lysine) (QC8222; TACH 101) is an inhibitor of the histone lysine demethylase 4D (KDM4D) with antitumor properties.Formule :C32H43N5O5Masse moléculaire :577.71M-525
CAS :M-525, a potent first-in-class menin-MLL inhibitor, binds at 3 nM IC50 and curbs MLL leukemia cell growth & gene expression.Formule :C39H51FN6O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :734.92CREB-IN-1 TFA
CREB-IN-1 TFA: Potent oral CREB inhibitor, IC50 of 0.18 μM, suppresses breast cancer cell growth.Couleur et forme :SolidZL-28-6
CAS :ZL-28-6, a type I PRMT inhibitor (IC50: 18 nM), effectively targets CARM1 (a member of PRMT) within cells and is suitable for cancer research [1].Formule :C18H22Cl2N2OCouleur et forme :SolidMasse moléculaire :353.29CEE321
CAS :CEE321 is an effective pan-JAK inhibitor with an IC50 of 54 nM. It effectively inhibits biomarkers associated with atopic dermatitis.Formule :C18H16ClN5OCouleur et forme :SolidMasse moléculaire :353.806JAK3 covalent inhibitor-1
CAS :JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM andFormule :C22H17FN6O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :448.47AMPTX-1
CAS :AMPTX-1 is a molecular glue functioning as a potent, selective, and reversible covalent degrader of BRD9 by recruiting it to the E3 ligase DCAF16.Formule :C42H53N5O4Couleur et forme :SolidMasse moléculaire :691.901HDAC/Top-IN-1
CAS :HDAC/Top-IN-1, an oral HDAC/Top inhibitor, targets HDAC1-3,6,8 with low IC50s; blocks S-phase & induces apoptosis in HEL cells.Formule :C29H25FN4O4Couleur et forme :SolidMasse moléculaire :512.53PAD2-IN-1 hydrochloride
PAD2-IN-1 hydrochloride: potent, selective PAD2 inhibitor; 95x less on PAD4, 79x less on PAD3; benzimidazole derivative.Formule :C25H30ClFN6O3Couleur et forme :SolidMasse moléculaire :517Tyk2-IN-14
CAS :Tyk2-IN-14, a small molecule inhibitor of TYK2, is significant in treating inflammatory diseases and conditions linked to hypersecretion of IFNa and interferons [1].Formule :C22H21N9O2Couleur et forme :SolidMasse moléculaire :443.46PARP1/2-IN-4
CAS :PARP1/2-IN-4 (compound 3) is an inhibitor of PARP1/2.Formule :C23H30FN5O6Couleur et forme :SolidMasse moléculaire :491.51MTL-CEBPA
MTL-CEPBA is a small activating RNA that targets C/EBPα upregulation and exhibits anti-inflammatory and anti-cancer effects.Couleur et forme :SolidBET-IN-27
CAS :BET-IN-27 (compound 6C) is an orally active BET inhibitor with IC50 values of 3.3 nM (BRD4-BD2), 3.4 nM (BRD4-BD1), 4.1 nM (BRD2-BD1), 20.4 nM (BRD3-BD1), and 42.0 nM (BRDT-BD1). It also exhibits antiproliferative activity.Formule :C21H23N5O3SCouleur et forme :SolidMasse moléculaire :425.5Aurora inhibitor 1
CAS :Aurora inhibitor 1 is a potent Aurora inhibitor (IC50: ≤ 4 nM and ≤13 nM for Aurora A and Aurora B kinase).Formule :C23H25N9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :459.57ORIC-944
CAS :ORIC-944 is an orally available, selective variant of PRC2 with anticancer activity for the study of prostate cancer.Formule :C26H25FN6ODegré de pureté :98.08%Couleur et forme :SolidMasse moléculaire :456.52Ref: TM-T87073
1mg84,00€5mg165,00€10mg237,00€25mg402,00€50mg515,00€100mg774,00€1mL*10mM (DMSO)À demanderINCB054329
CAS :INCB054329 is a BET inhibitor targeting BRD2/3/4 and BRDT with IC50s ranging from 1-119 nM.Formule :C19H16N4O3Degré de pureté :99.52%Couleur et forme :SolidMasse moléculaire :348.36Pocenbrodib
CAS :Pocenbrodib (FT-7051) is a potent inhibitor of the bromodomain of the CBP/p300 family with potential antitumour activity and is palatable for cancer research.Formule :C28H32FN3O6Degré de pureté :98.48% - 99.54%Couleur et forme :SolidMasse moléculaire :525.57EZM0414
CAS :EZM0414 is a potent, selective, orally bioavailable inhibitor of SETD2 with IC50 of 18 nM in SETD2 biochemical assay and IC50 of 34 nM in a cellular assay.Formule :C22H29FN4O2Degré de pureté :99.58%Couleur et forme :SolidMasse moléculaire :400.49GSK3368715 dihydrochloride
CAS :GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) is a PRMTs inhibitor , with anticancer activity, for the study of advanced solid tumors.Formule :C20H40Cl2N4O2Degré de pureté :99.66% - 99.66%Couleur et forme :SolidMasse moléculaire :439.46AMG-193
CAS :AMG-193 is an inhibitor of the MTA-PRMT5 complex and is used in the study of cancer, respiratory diseases and digestive disorders.Formule :C22H19F3N4O3Degré de pureté :99.52%Couleur et forme :SolidMasse moléculaire :444.41Aldometanib
CAS :Aldometanib (LXY-05-029) is an oral aldolase inhibitor that maintains metabolic balance by blocking FBP and activating lysosomal AMPK.Formule :C27H43Cl2IN2Degré de pureté :99.32% - 99.55%Couleur et forme :SolidMasse moléculaire :593.46LLY-283
CAS :LLY-283, PRMT5 inhibitor, IC50 22 nM, Kd 6 nM, oral, selective, with antitumor effects.Formule :C17H18N4O4Degré de pureté :99.49%Couleur et forme :SolidMasse moléculaire :342.35YTH-IN-1
CAS :YTH-IN-1 is an inhibitor of the five YTH structural domains in the human.The YTH family of proteins is an N 6-methyladenosine (m6A) reader in gene expression.Formule :C18H24N6O3Degré de pureté :98.46% - 99.94%Couleur et forme :SolidMasse moléculaire :372.42BAY-3827
CAS :BAY-3827 is an AMPK inhibitor with antiproliferative activity and antitumor activity. BAY-3827 inhibits the phosphorylation of acetyl CoA carboxylase 1.Formule :C27H25FN6ODegré de pureté :99.90%Couleur et forme :SolidMasse moléculaire :468.53Ref: TM-T73350
1mg56,00€5mg119,00€10mg187,00€25mg354,00€50mg590,00€100mg835,00€500mg1.663,00€1mL*10mM (DMSO)124,00€DN02
DN02: a potent, selective BRD8(1) bromodomain probe; Ki=32 nM; 30x more affine than BRD8(2).Formule :C22H24FN3O3Degré de pureté :98.22% - 99.74%Couleur et forme :SolidMasse moléculaire :397.44BRD0639
CAS :BRD0639 is a first-in-class PRMT5-substrate interaction inhibitor for PBM-dependent PRMT5 activity studies.Formule :C21H22ClN5O4SDegré de pureté :99.85%Couleur et forme :SolidMasse moléculaire :475.95JDTic
CAS :JDTic, a 4-phenylpiperidine derivative distantly related to analgesics like meperidine and ketobemidone and more closely to the mu opioid antagonist alvimopan, exhibits a notably long duration of action, maintaining effects in animals for weeks following a single dose. This duration is not due to irreversible binding to the kappa opioid receptor but rather to altered activity of c-Jun N-terminal kinases. As a highly selective antagonist for the κ-opioid receptor, without influencing the μ- or δ-opioid receptors, JDTic has shown potential in animal studies for producing antidepressant and anxiolytic effects. It also demonstrates promise in treating addiction to substances such as cocaine and morphine, distinguishing itself structurally from other kappa antagonists like norbinaltorphimine.Formule :C28H39N3O3Couleur et forme :SolidMasse moléculaire :465.63Sinefungin
CAS :Sinefungin (Adenosyl-Ornithine) is an effective inhibitor of virion mRNA(guanine-7-)-methyltransferase, mRNA(nucleoside-2'-)-methyltransferase, and viralFormule :C15H23N7O5Degré de pureté :98% - 98.12%Couleur et forme :SolidMasse moléculaire :381.39EHMT2-IN-2
CAS :EHMT2-IN-2 Used in the research of blood disease or cancer. EHMT2-IN-2 is a potent EHMT inhibitor, with IC50s of all <100 nM for EHMT1 peptide, EHMT2 peptide and cellular EHMT2.Formule :C21H22N6OCouleur et forme :SolidMasse moléculaire :374.44(8R,9S)-Talazoparib
CAS :(8R,9S)-Talazoparib is Talazoparib enantiomer , less active than Talazoparib on the inhibition of PARP1 (IC50: 144 nM).Formule :C19H14F2N6OCouleur et forme :SolidMasse moléculaire :380.35YF-2 hydrochloride
CAS :YF-2 hydrochloride is a potent histone acetyltransferase activator that exhibits high selectivity and can pass through the blood-brain barrier. It specifically acetylates H3 in the hippocampus, with EC50 values of 2.75 μM, 29.04 μM, and 49.31 μM for CBP, PCAF, and GCN5, respectively. Notably, it does not affect HDAC activity. Moreover, YF-2 hydrochloride demonstrates promising anti-cancer and anti-Alzheimer's disease properties.Formule :C20H23Cl2F3N2O3Couleur et forme :SolidMasse moléculaire :467.31Cercosporin
CAS :Cercosporin, produced by the plant pathogen Cercospora kikuchii and the elsinochromes, is a potent photosensitizer with a short activation wavelength. Cercosporin contains perylene quinone structural features essential for PKC activity (IC50: 0.6-1.3 μM).Formule :C29H26O10Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :534.51PLK1-IN-6
PLK1-IN-6: potent, selective PLK1 inhibitor, IC50 = 0.45 nM, hinders cancer cell growth.
Formule :C28H37N9O3Couleur et forme :SolidMasse moléculaire :547.65HJB97
CAS :HJB97 is used for the design of potential PROTAC BET degrader. It also has antitumor activity. HJB97 is a high-affinity inhibitor of BET (Kis: 0.9 nM (BRD2 BD1), 0.27 nM (BRD2 BD2), 0.18 nM (BRD3 BD1), 0.21 nM (BRD3 BD2), 0.5 nM (BRD4 BD1), 1.0 nM (BRD4 BD2), respectively).Formule :C26H28N8O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :500.55BD-9136
BD-9136, a highly selective BRD4 degrader, demonstrates the capability to inhibit tumor growth without inducing adverse effects in mice, showing potential forFormule :C44H44N10O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :824.95Amredobresib
CAS :Amredobresib is a potent BET inhibitor that impedes the interaction between bromodomains and acetylated lysines on histone H3 and H4, thereby serving as crucial regulators of gene transcription. It proves valuable in the investigation of acute myeloid leukemia (AML) and cancer.Formule :C26H29N9Couleur et forme :SolidMasse moléculaire :467.581(3R,4S)-Tofacitinib
CAS :(3R,4S)-Tofacitinib, the less active enantiomer of Tofacitinib, is a JAK3 inhibitor with an IC50 of 1 nM.Formule :C16H20N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :312.37CARM1-IN-1 hydrochloride
CAS :CARM1-IN-1 hydrochloride is a potent and selective inhibitor of CARM1 (IC50: 8.6 μM) with minimal inhibition of PRMT1 and SET7.Formule :C26H22Br2ClNO3Couleur et forme :SolidMasse moléculaire :591.72HIF-PHD-IN-1
CAS :HIF-PHD-IN-1 is a pharmacological compound that acts as an orally active inhibitor of the hypoxia-inducible factor prolyl hydroxylase domain (HIF-PHD), displaying an IC50 of 54 nM for hHIF-PHD2. Its potential as a therapeutic agent for renal anemia is highly promising.Formule :C17H12Cl2N6O3Couleur et forme :SolidMasse moléculaire :419.22Desidustat
CAS :Desidustat is an inhibitor of HIF hydroxylase.
Formule :C16H16N2O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :332.31Ref: TM-T5176
Produit arrêtéCTB
CAS :CTB (Cholera Toxin B subunit) is an activator of p300 histone acetyltransferase and induces apoptosis in MCF-7 cells.
Formule :C16H13ClF3NO2Degré de pureté :99.82%Couleur et forme :SolidMasse moléculaire :343.73PF-03814735
CAS :PF-03814735 is a novel, potent and reversible inhibitor of Aurora A/B with IC50of 0.8 nM/5 nM, is less potent to Flt3, FAK, TrkA, and minimally active to Met and FGFR1. Phase 1.Formule :C23H25F3N6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :474.48Bisindolylmaleimide I HCl
CAS :Bisindolylmaleimide I HCl is a specific ATP-competitive PKC inhibitor.Formule :C25H25ClN4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :448.95BET-IN-15
CAS :BET-IN-15 (compound 1) is a potent, orally active inhibitor of BET, demonstrating inhibitory IC50 values of 0.64 nM for BRD4-BD1 and 0.25 nM for BRD4-BD2.
Formule :C21H18F2N4O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :444.45AMPK activator C2
CAS :AMPK activator C2 is an AMPK allosteric activator.Formule :C7H6NO6PDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :231.1BLL5 Maleate
CAS :BLL5 Maleate is a first-in-class selective PRMT5 inhibitor, it blocks EBV-driven B lymphocyte transformation and survival while leaving normal B cells unaffected.Formule :C21H21N3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :315.41JAK2-IN-9
CAS :Compound A8, known as JAK2-IN-9, is a selective JAK2 inhibitor with an IC50 of 5 nM.
Formule :C20H24N6O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :412.51Antitumor agent-104
CAS :Antitumor Agent-104 (Compound 9) serves as an antineoplastic by impeding DNA repair mechanisms in tumor cells, primarily through the inhibition of PARP1 enzyme
Formule :C31H33FN6O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :556.63JAK-IN-34
CAS :JAK-IN-34 (compound 11n) is a potent inhibitor of Janus kinases (JAKs), demonstrating IC50 values of 0.40 nM for JAK1, 0.83 nM for JAK2, 2.10 nM for JAK3,
Formule :C27H26N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :450.53STAT3-IN-18
CAS :STAT3-IN-18 (compound SPP), a platinum (IV) complex featuring an axial ligand from sandalwood, suppresses the JAK2-STAT3 pathway in breast cancer (BC) cells and
Formule :C18H24Cl2N2O6PtDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :630.38Lerzeparib
CAS :Lerzeparib is a PARP (ADP-ribose polymerase) inhibitor that exhibits antineoplastic activity [1].
Formule :C21H20FN3O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :365.4BBDDL2059
CAS :BBDDL2059 is a selective covalent inhibitor targeting EZH2, exhibiting an IC50 of 1.5 nM against the EZH2-Y641F mutant.
Formule :C27H36N4O4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :512.66JAK1-IN-10
CAS :JAK1-IN-10 (compound 9), a cyano-substituted cyclic hydrazine derivative, functions as a potent and selective inhibitor of JAK1 [1].
Formule :C15H17N7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :295.34JAK1-IN-11
CAS :JAK1-IN-11 (compound 11) serves as a potent inhibitor of Janus kinases, exhibiting nanomolar inhibitory concentrations with IC50 values of 0.02 nM (JAK1) and 0.
Formule :C26H36N6O4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :528.67BAZ2-ICR
CAS :BAZ2-ICR is an epigenetic chemical probe and it also is a potent, selective, cell active and orally active BAZ2A/B bromodomains inhibitor with IC50s of 130 nM and 180 nM, and Kds of 109 nM and 170 nM, respectively. BAZ2-ICR shows 10-15-fold selectivity for binding BAZ2A/B over CECR2 and >100-fold selectivity over all other bromodomains.Formule :C20H19N7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :357.41Igermetostat
CAS :Igermetostat, an EZH2 inhibitor, is utilized both in vivo and in vitro for cancer research [1].
Formule :C32H46N4O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :550.73DPP
CAS :DPP, a Platinum(IV) complex with a pterostilbene-derived axial ligand, inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, demonstrating
Formule :C36H40Cl2N2O10PtDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :926.7JAK-IN-27
CAS :JAK-IN-27, also known as compound 1, is an orally active, potent inhibitor of the JAKS family kinases, displaying inhibitory concentrations (IC50s) of 3.0 nM
Formule :C20H21F2N7ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :413.42BET-IN-14
CAS :BET-IN-14 is a pan BET inhibitor with an IC50 of 5.35 nM, demonstrating oral activity and anticancer properties [1].
Formule :C30H37N7O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :527.66BET BD2-IN-3
CAS :BET BD2-IN-3 (compound I-58), a BET inhibitor specifically targeting the BD2 domain, can be radiolabeled with [11C] for use in positron emission tomography (PET) imaging. PET studies with [11C]BD2-IN-3 in mice have demonstrated appropriate biodistribution in peripheral organs and tissues.
Formule :C29H30N4OCouleur et forme :SolidMasse moléculaire :450.58PARP7-IN-16 free base
CAS :PARP7-IN-16 free base is the freebase form of PARP7-IN-16. As a selective oral inhibitor of PARP-1/2/7, it demonstrates IC50 values of 0.94, 0.87, and 0.21 nM, respectively. This compound is utilized in the research of breast and prostate cancer.
Formule :C25H27FN4O4Couleur et forme :SolidMasse moléculaire :466.50BB-Cl-Amidine hydrochloride
CAS :BB-Cl-Amidine hydrochloride is an inhibitor of peptidylarginine deminase (PAD) [1].Formule :C26H27Cl2N5ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :496.43
